![Elias Papatheodorou](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elias Papatheodorou
Chief Executive Officer at
Calliditas Therapeutics Suisse SA
Profile
Elias Papatheodorou is currently Chief Executive Officer & Director at Calliditas Therapeutics Suisse SA since 2015.
Since 2022, holds the position of Chief Executive Officer & Managing Director at HepaRegeniX GmbH, with the managing director title starting in 2024.
Also serves as Director at Tribune Therapeutics AB. Former roles include Chief Executive Officer at Novosom Verwaltungs GmbH from 2004 to 2009, Chief Executive Officer at Genticel SA, Chief Executive Officer & Director at Calliditas Therapeutics France SAS from 2017 to 2021, Chairman at Priaxon AG, Independent Chairman at Memo Therapeutics AG, Senior VP-Business Development & Operations at MediGene AG, Principal at Philip Morris USA, Inc., and Chief Business Officer at Covagen AG.
Education includes undergraduate studies at Ithaca College and graduate studies at Cornell University.
Elias Papatheodorou active positions
| Companies | Position | Start |
|---|---|---|
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Develops small molecule therapeutics that selectively inhibit NOX enzymes | Chief Executive Officer | - |
HepaRegeniX GmbH
 HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Chief Executive Officer | 21/10/2024 |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Operates as preclinical biopharmaceutical company that develops medicines to treat patients with fibrotic diseases | Director/Board Member | - |
Former positions of Elias Papatheodorou
| Companies | Position | End |
|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Chairman | 07/07/2024 |
| GENKYOTEX SA. | Chief Executive Officer | 30/11/2021 |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus | Chief Executive Officer | - |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery company for small molecule therapeutics | Chairman | - |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Corporate Officer/Principal | - |
Training of Elias Papatheodorou
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
12
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Develops small molecule therapeutics that selectively inhibit NOX enzymes | Health Technology |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Ithaca College
 Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philip Morris USA, Inc.
 Philip Morris USA, Inc. TobaccoConsumer Non-Durables Manufactures and distributes cigarettes and related tobacco products | Consumer Non-Durables |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery company for small molecule therapeutics | Commercial Services |
Novosom Verwaltungs GmbH
 Novosom Verwaltungs GmbH BiotechnologyHealth Technology Develops liposomal technology for the delivery of DNA based therapeutics | Health Technology |
Genticel SA
Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Health Technology |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Engages in biotechnology research and development | Commercial Services |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Operates as preclinical biopharmaceutical company that develops medicines to treat patients with fibrotic diseases | Commercial Services |
- Stock Market
- Insiders
- Elias Papatheodorou
